Finland· FI-REL-REL63918
Korjuny
A catumaxomab product containing catumaxomab, registered in Finland by Atnahs Pharma Netherlands B.V.. The same ATC class is registered in 2 of our 19 countries.
Checked against Fimea (Finland) on
Informational only — not a medical device.
Where it is registered
Catumaxomab is registered in 2 of 19 countries.
Countries holding a registration under ATC L01XC09 (catumaxomab), each read from that country’s own register.
- This record: Finland, from Fimea (Finland)
- 2 of them publish a price we can compare per daily dose
Catumaxomab · ATC L01XC09
2 / 19 countries
- Belgiumprice
- Finlandprice
The record
At a glance
Fimea (Finland)- Active substance
- Catumaxomab
- Manufacturer
- Atnahs Pharma Netherlands B.V.
- Country
- Finland (FI)
- ATC code
- L01XC09
- ATC class
- Catumaxomab
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Catumaxomab in 9 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- IrelandKorjuny 50 micrograms concentrate for solution for infusionAtnahs Pharma Netherlands B.V.
- NetherlandsKorjuny 50 microgram, concentraat voor oplossing voor infusieAtnahs Pharma Netherlands B.V.
- SpainKORJUNY 10 MICROGRAMOS CONCENTRADO PARA SOLUCION PARA PERFUSIONAtnahs Pharma Netherlands Bv.
- BelgiumKorjuny 10 µgAtnahs Pharma Netherlands
- IcelandKorjunyAtnahs Pharma Netherlands B.V.
- PolandKORJUNYLindis Biotech GmbH
- SwedenKorjuny 10 mikrogram Koncentrat till infusionsvätska, lösningAtnahs Pharma Netherlands B.V.
- CzechiaKORJUNYAtnahs Pharma Netherlands B.V., Amsterdam
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Korjuny
- Liechtenstein · Korjuny
- Norway · Korjuny
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/0fdd37c0-b514-4961-9efe-92681589c540 GET /v1/drugs/0fdd37c0-b514-4961-9efe-92681589c540?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": null,
"form": "infuusiokonsentraatti, liuosta varten",
"route": "Vatsaonteloon",
"ddd_unit": null,
"strength": "50 mikrog",
"atc_label": "katumaksomabi",
"ma_number": null,
"auth_status": "Myyntilupa myönnetty",
"eu_ma_number": "EU/1/24/1826/002",
"fimea_rel_id": "REL63918",
"authorised_at": "2025-02-10"
}See everything about catumaxomab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.